Abstract
We have undertaken a prospective randomized trial of one month's antimicrobial therapy for patients with symptomatic relapse of Crohn's disease. Criteria for entry included two major symptoms: fever, abdominal pain, diarrhea, weight loss, abdominal mass or complications (excluding perianal disease); and two hematologic abnormalities: hemoglobin, ESR, albumin, C reactive protein, iron, or total iron binding capacity. Patients were monitored for the aforementioned clinical and hematologic (hemoglobin, albumin, CRP) parameters over six weeks and for changes in fecal flora. Randomization was to four groups: metronidazole alone (M), cotrimoxazole alone (C), metronidazole and cotrimoxazole (C plus M), or double placebo (P). Seventy-two patients entered the study (18=M, 16=C 21=C plus M, 17=P). After two weeks, improvement was reported as follows: M=67 percent, C=17 percent, C plus M=71 percent, P=35 percent. In the metronidazole group, two patients required surgery and one had trouble-some side effects. In the cotrimoxazole group, two had side effects. In the combined group (C plus M), four had troublesome side effects and two of the placebo group (P) required operation. By four weeks, there was no difference in response among the groups: (M=44 percent, C=62 percent, C plus M=57 percent, P=41 percent). Antimicrobials had no effect on fecal flora or hematologic parameters. These results indicate that antimicrobials have little therapeutic potential for relapse of intestinal Crohn's disease.
Similar content being viewed by others
References
Crohn BB, Ginzberg L, Oppenheimer GD. Regional ileitis: a pathological clinical entity. JAMA 1932;99:1323–9.
Dalziel TK. Chronic intestinal enteritis. Br Med J 1913;2:1068–70.
Keighley MR, Arabi Y, Dimock F. Influence of inflammatory bowel disease on intestinal flora. Gut 1978;17:1099–1104.
Ambrose NS, Youngs D, Burdon DW, Keighley MR. Changes in intestinal microflora in Crohn's disease. Br J Surg 1982;69:681.
Aluwihare AP. Electron microscopy in Crohn's disease. Gut 1971; 12:509–18.
Ambrose NS, Johnson M, Burdon DW, Keighley MR. Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during Crohn's disease surgery. Br J Surg 1984;71:623–5.
Bernstein CH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357–65.
Ursing B, Kamme C. Metronidazole for Crohn's disease. Lancet 1975;1:775–7.
Blichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn's disease: a double blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123–7.
Allan R, Cooke WT. Evaluation of metronidazole in the management of Crohn's disease. Gut 1977;18:422.
Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulphasalazine for active Crohn's disease. The cooperative Crohn's disease study in Sweden: the result. Gastroenterology 1982;83:550–62.
Maldrow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249–66.
Moss AA, Cerbone JV, Kressel HY. Radiological and clinical assessment of broad spectrum antibiotic therapy in Crohn's disease. Roentgenology 1978;131:787–90.
Krook A, Jarnerot G, Daniellson D. Clinical effect of metronidazole and sulphasalazine on Crohn's disease in relation to changes in faecal flora. Scand J Gastroenterol 1981;16:569–75.
Keighley MR, Youngs D, Johnson M, Burdon DW.Clostridium difficile toxin in acute diarrhoea complicating inflammatory bowel disease. Gut 1982;23:410–4.
Arabi Y, Dimock F, Burdon DW. Influence of bowel preparation and antimicrobials on aerobic microflora. Br J Surg 1978;65:555–9.
Krook A. The effect of metronidazole and sulphasalazine on the normal human faecal flora. Scand J Gastroenterol 1981;16:587–92.
Krook A, Daniellson D, Kjellander J, Jarnerot G. The effect of metronidazole and sulphasalazine on faecal flora in patients with Crohn's disease. Scand J Gastroenterol 1981;16:183–92.
Hudson MJ, Elliot PR, Burnham WR, Hill MJ, Lennard-Jones JE. The microbial flora of faeces and rectal mucosa in Crohn's disease before and during antimicrobial therapy (abstract). Proceedings of the Pathological Society of Great Britain and Ireland. J Med Microbiol 1983;16:2,iii.
Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980;1:514.
Elliott PR, Lennard-Jones JE, Hathaway M. Simple index of Crohn's disease. Lancet 1980;1:876.
Jensen KB, Jarnum S, Kondahl G, Kristen SC. Serum orosomucoids and ulcerative colitis: its relation to clinical activity protein loss and turnover of albumin and IgA. Scand J Gastroenterol 1976;11:177–83.
Saverymuttu S, Keshavarzian A, Gupta A, Donovan B, Hodgson HJ. Evaluation of short term treatment of Crohn's disease with slow release 5 aminosalicylic acid (abstract). Gut (In press).
Ambrose NS, Goldman M, Hawker RJ, Drole Z, Keighley MR, McCollum CN. The differentiation between abscess formation and active Crohn's disease using Indium-III labelled leucocyte gamma imaging. Gut 1983;24:A463.
Burdon DW, Brown JD, Youngs DJ, et al. Antibiotic susceptibility ofClostridium difficile. JAC 1979;5:37–310.
West B. Effects of sulphasalazine (Salasopyrine) on faecal flora in patients with inflammatory bowel disease. Gut 1974;15:960–65.
Ambrose NS, Johnson M, Burdon DW, Keighley MR. The influence of single dose intravenous antibiotics on faecal flora and emergence ofClostridium difficile. JAC (In press).
Grove DI, Mahmood AA, Warren KS. Suppression of cell initiated immunity by metronidazole. Clin Res Suppl 1976;24:285.
Kasper DC. Quantitative determination of the antibody response to the intra-abdominal abscess formation. J Infect Dis 1977;136:789–95.
Author information
Authors and Affiliations
About this article
Cite this article
Ambrose, N.S., Allan, R.N., Keighley, M.R.B. et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. Dis Colon Rectum 28, 81–85 (1985). https://doi.org/10.1007/BF02552649
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02552649